Plain-English translation of NCT06562400 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is looking for new ways to help people with frequent migraines who haven't benefited enough from newer migraine medications called monoclonal antibodies. Researchers want to understand why about one-third of patients don't respond to these medications, and explore whether changes to diet or other biological treatments might provide relief. The study will examine blood samples and health information from people whose migraines remain poorly controlled despite treatment.
Even though newer migraine medications have been a major breakthrough, many patients still have frequent debilitating headaches or don't respond to the medication at all. Doctors need to understand the biological reasons why this happens so they can develop better treatment options and help more people find relief.
You likely qualify if…
You likely don't qualify if…
You would share your medical history and allow researchers to collect blood samples and health information to study the biological reasons some people don't respond well to migraine medications. The study will analyze your samples and medical records over time to better understand how your body responds to treatment and explore whether dietary approaches or other biological factors might help reduce your migraines. You would be in the non-responder or partial-responder group depending on how well you've responded to your current migraine medication.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Italy
Sponsor
IRCCS National Neurological Institute "C. Mondino" Foundation
Collaborators
University of L'Aquila
Enrollment target
~45 participants
Started
May 2023
Primary completion
October 2024
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in August 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Roberto De Icco
IRCCS National Neurological Institute "C. Mondino" Foundation
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.